

EPIX MEDICAL INC  
Form 8-K  
August 05, 2004

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **August 5, 2004**

## EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**000-21863**  
(Commission  
File Number)

**04-3030815**  
(IRS Employer  
Identification No.)

**71 Rogers Street**  
**Cambridge, Massachusetts 02142**

(Address of principal executive offices) (Zip Code)

Edgar Filing: EPIX MEDICAL INC - Form 8-K

Registrant's telephone number, including area code: **(617) 250-6000**

---

**Item 5. Other Events.**

On August 5, 2004, EPIX Medical, Inc. issued a press release announcing that it has initiated its first human clinical trial of EP-2104R, an injectable MRI contrast agent which specifically targets blood clots, or thrombi, in the body. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated August 5, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EPIX Medical, Inc.**  
**(Registrant)**

Date: August 5, 2004

/s/ Peyton J. Marshall  
Peyton J. Marshall  
*Senior Vice-President,  
Finance and Administration,  
Chief Financial Officer*